Extended partnership for 15 years and expand footprint to include Brazil

MONTEVIDEO, Uruguay – June, 2017
Grupo Biotoscana (GBT), a leading specialty pharmaceutical company in Latin America, announces the extension of the partnership with Pint Pharma (“Pint”) for 15 years and the inclusion of Brazil into their agreement.

GBT maintains all its rights under prior agreement to promote, market, sell and distribute Alprostapint in different countries in the region and get an extension for 15 years. This agreement confirms the intensification of the years-long partnership between GBT and Pint Pharma, including the territory expansion to Brazil, that highlights the importance of GBT´s regional footprint strategy.

GBT and Pint initiates a Joint Clinical Development program that includes a potential Phase III study and several post-registration clinical extensions in several Latin American countries.

GBT is very enthusiastic to be able to expand this existing partnership to Brazil and enhance clinical profile of Alprostapint to serve more patients and doctors with this leading drug.

About GBT
Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical and LKM. GBT‘s strong portfolio combines world-class licenses and proprietary products. GBT is controlled by a global private equity firm Advent International, with other significant shareholders including Essex Woodlands and several private investors.

To find out more about Grupo Biotoscana, please go to www.grupobiotoscana.com

About Pint Pharma GmbH
Pint Pharma GmbH develops, manufactures, markets, and distributes pharmaceutical products in Central and South America. It offers originator drugs that focus on rare diseases; and niche therapeutic hospital products with a focus on oncology and specialty pharma. Pint Pharma GmbH was founded in 1993 and is headquartered in Vienna, Austria. It has commercial operations in Colombia, Mexico, Brazil, Venezuela, Peru, Switzerland, Austria, Argentina, Chile, Ecuador, and the Dominican Republic. To find out more, please visit: http://www.pint-pharma.com/

About Alprostapint
Alprostapint indicated for cardiovascular diseases, specifically for peripheral artery occlusive disease at Fontaine stages 3 or 4 when other alternative treatment is not possible or proved ineffective.

Forward-Looking Statements (GBT)
This release includes forward-looking statements concerning a transaction between Pint Pharma and GBT-Grupo Biotoscana, including expectations regarding the applicability of predictions to the commercialization of certain products. GBT-Grupo Biotoscana disclaims any obligation to update any forward-looking statement, except as required by applicable law.

Contacts:

GBT – Grupo Biotoscana
Román Saglio
EVP Marketing
Melissa Angelini
IR Manager
Tel: +55 11 5090 7233
ri@grupobiotoscana.com

GBT – Press
Raul Fagundes Neto / Fernando Marchi
Medialink (São Paulo)
Tel: +55 11 3817 2131
raul.fagundes@medialink.com.br

Updated on 01/02/2019 at 05:01 pm